Skip to main content
Premium Trial:

Request an Annual Quote

Viewpoint Molecular Targeting Treats First Neuroendocrine Cancer Patients With Radiopharmaceutical

NEW YORK – Viewpoint Molecular Targeting on Monday said it has treated the first two neuroendocrine cancer patients with its investigational radiopharmaceutical VMT-a-NET.

According to Viewpoint Molecular Targeting, based in Coralville, Iowa, these two patients received VMT-a-NET in India under a compassionate use program as opposed to within a clinical trial. Viewpoint provided the isotopes and supplies for drug production and oversaw its manufacturing locally. BJ Madan, a New Delhi-based diagnostic and therapeutic radiopharmaceutical company, collaborated with the patients' physician Ishida Sen to administer the therapy. Over the course of the next few months, Sen and her team plan to follow the patients' progress and report on the treatment's safety and efficacy.

The patients treated with VMT-a-NET did not experience any adverse reactions within the first 10 days, Viewpoint Molecular Targeting said. The radiopharmaceutical is designed to target somatostatin receptor subtype 2 (SSTR2) on the surface of neuroendocrine tumors and deliver the alpha-emitting isotope lead-212 to the cancer cells. The company is also developing a complementary imaging agent to identify patients with SSTR2-expressing tumors who will receive the radiotherapy. The patients treated with VMT-a-NET in India had SSTR2-expressing neuroendocrine tumors.

As for a legitimate planned clinical trial, the firm said a Phase I study is expected to begin in the US "imminently" but did not share a specific time frame.